Back to search

Aristotle University Of Thessaloniki (AUTH)

Ανάπτυξη πεπτιδικών ραδιοφαρμάκων με εφαρμογή στην ογκολογία

Abstract

dc:description

Mapping of peptide receptors which overexpressed on the surface of various types of cancer cells has been in recent years the basis for in vivo molecular targeting of neoplastic diseases with radiolabeled peptides. Therefore, a significant number of peptide analogs have been designed to date in order to deliver appropriate diagnostic and therapeutic radionuclides selectively to cancer targets. In this way they offer individualized treatment of cancer for each patient in the context of "molecular diagnosis and treatment".The present thesis focuses on the development of peptide GRPR-antagonists radiolabeled with diagnostic and therapeutic radionuclides with improved biological characteristics, such as high metabolic stability and desirable biokinetics. It has initially included the comparison of biological behavior, with emphasis on pharmacokinetics in mice with human GRPR-positive xenografts, a GRPR-antagonist and an agonist with similar chemical structure. Afterwards, an attempt was made to increase the metabolic stability by targeted structural modification of the peptide sequence of a GRPR-antagonist, while the effect of different radiometals was evaluated on the stability and biological elements of the formed radiopeptides. Finally, subject of extensive study was the determination of the activity of the proteolytic enzyme NEP in a series of radiolabeled GRPR-antagonists, the definition of degradation sites, as well as the possibility of in-situ inhibition of its action in order to increase in vivo metabolic stability.In this context, two new GRPR-antagonists were designed and synthesized, SB4 and SB9, the well-known GRPR antagonist SB3, as well as its potential degradation products, metabolites M1-5. Their synthesis was carried out according to the solid phase synthesis strategy by Fmoc protection method and their identification was performed using RP-HPLC and MALDI-TOF MS.The results of in vitro & in vivo studies verified the superior pharmacokinetic and higher stability for the GRPR-antagonist [111In]SB9 versus the agonist [111In]AMBA, fact which is in consistent with the general perception that GRPR-antagonists are preferable relative to the respective agonists for the imaging and treatment of cancer tumors. Replacement of glycine-11 by D-alanine in the peptide sequence was confirmed as an effective way to increase metabolic stability, considering that [111In]SB4 appeared to be significantly more stable than [111In]SB3. However, this modification had a negative impact on the ability of SB4 to bind to GRPR and after all to the ability of targeting experimental PC-3 tumors for [111In]SB4. Finally, for all analogues, the possibility of further improvement of pharmacokinetics was demonstrated through in situ stabilization of radiopeptide analogues with the co-administration of the NEP inhibitor, PA. By the contribution of the original radiometabolites, which may be formed according to the literature and synthesized for this purpose, and by the application of radioanalytic chromatographic comparison methods, the degradation sites by NEP in the sequence of radiopeptides [111In/177Lu]SB3 were identified

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Lymperis, Emmanouil
  • Λυμπέρης, Εμμανουήλ

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52432

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Lymperis, Emmanouil; Λυμπέρης, Εμμανουήλ. Ανάπτυξη πεπτιδικών ραδιοφαρμάκων με εφαρμογή στην ογκολογία. Aristotle University Of Thessaloniki (AUTH), 2022. http://hdl.handle.net/10442/hedi/52432